Scientific context only. Not medical advice, not a recommendation to use.
At a glance
Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet.
Researched for
Weight reduction in obesity (CagriSema programme)Glycaemic control in type 2 diabetes
Official status
US: Unapproved
No FDA approval. Phase-3 trials of the CagriSema programme are ongoing (REDEFINE).
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
3 observations · single evidence tier
Human RCT
3
03
What the studies show
Human RCT
Mensch
Enebo LB. et al. 2021
Additional weight reduction in combination with semaglutide 2.4 mg versus semaglutide monotherapy observed in the phase-2 CagriSema trial
What does NOT follow: Phase 2 with moderate sample size; phase-3 results pending.
Human RCT
Mensch
Lau DCW. et al. 2021
Monotherapy showed weight reduction of similar magnitude to GLP-1 RA comparator arms in a phase-2 study
What does NOT follow: Dose-finding study without active comparator in the same arm.
Human RCT
Mensch
Lau DCW. et al. 2021
Gastrointestinal adverse events (nausea) were frequent and dose-dependent in the phase-2 studies
What does NOT follow: Profile similar to other incretin- and amylin-modulating substances.
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 168 h. Pure pharmacokinetic model — not a dosing recommendation.
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Subcutaneous
Administered weekly subcutaneously in all published trials.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human RCT
Nausea
Most frequently documented event in the phase-2 trial.
häufig, dosisabhängig
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
11
Legal status by country
Country
Status
Note
Checked
United States
Unapproved
No FDA approval. Phase-3 trials of the CagriSema programme are ongoing (REDEFINE).
2026-05-22
Germany
Unapproved
No EMA approval. Availability only within clinical trials.
2026-05-22
DK
Unapproved
Phase-3 clinical trials are conducted predominantly by Novo Nordisk (Denmark).
2026-05-22
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management